Statement of Ownership (sc 13g)
April 24 2020 - 05:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
InVivo
Therapeutics Holdings Corp. |
(Name of Issuer) |
Common Stock, $0.00001 par
value |
(Title of Class of Securities) |
April 15, 2020 |
(Date of Event Which Requires Filing of this
Statement) |
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
[_]
Rule 13d-1(b)
[X]
Rule 13d-1(c)
[_]
Rule 13d-1(d)
__________
* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided
in a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
1. |
NAME OF
REPORTING PERSONS |
|
|
|
|
|
Armistice Capital,
LLC |
|
|
|
|
2. |
CHECK THE APPROPRIATE
BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) |
|
|
(a) [_] |
|
|
(b) [_] |
|
|
|
3. |
SEC USE ONLY |
|
|
|
|
|
|
|
4. |
CITIZENSHIP OR PLACE OF
ORGANIZATION |
|
|
|
|
|
Delaware |
|
|
|
|
NUMBER OF SHARES
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
|
|
|
5. |
SOLE VOTING POWER |
|
|
|
|
|
0 |
|
|
|
|
6. |
SHARED VOTING POWER |
|
|
|
|
|
254,597 |
|
|
|
|
7. |
SOLE DISPOSITIVE
POWER |
|
|
|
|
|
0 |
|
|
|
|
8. |
SHARED DISPOSITIVE
POWER |
|
|
|
|
|
254,597 |
|
|
|
|
9. |
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
|
254,597 |
|
|
|
|
10. |
CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |
|
|
|
[_] |
|
|
|
11. |
PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW (9) |
|
|
|
|
|
4.99% |
|
|
|
|
12. |
TYPE OF REPORTING PERSON (SEE
INSTRUCTIONS) |
|
|
|
|
|
IA,
OO |
|
1. |
NAME OF
REPORTING PERSONS |
|
|
|
Armistice Capital Master Fund
Ltd. |
|
|
2. |
CHECK THE APPROPRIATE
BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) |
|
|
(a) [_] |
|
|
(b) [_] |
|
|
3. |
SEC USE ONLY |
|
|
|
|
4. |
CITIZENSHIP OR PLACE OF
ORGANIZATION |
|
|
|
Cayman Islands |
|
|
NUMBER OF
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
|
|
5. |
SOLE VOTING POWER |
|
|
|
0 |
|
|
6. |
SHARED VOTING POWER |
|
|
|
254,597 |
|
|
7. |
SOLE DISPOSITIVE
POWER |
|
|
|
0 |
|
|
8. |
SHARED DISPOSITIVE
POWER |
|
|
|
254,597 |
|
|
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
254,597 |
|
|
10. |
CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |
|
[_] |
|
|
11. |
PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW (9) |
|
|
|
4.99% |
|
|
12. |
TYPE OF REPORTING PERSON (SEE
INSTRUCTIONS) |
|
|
|
CO |
1. |
NAME OF
REPORTING PERSONS |
|
|
|
|
|
Steven Boyd |
|
|
|
|
2. |
CHECK THE APPROPRIATE
BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) |
|
|
(a) [_] |
|
|
(b) [_] |
|
|
|
3. |
SEC USE ONLY |
|
|
|
|
|
|
|
4. |
CITIZENSHIP OR PLACE OF
ORGANIZATION |
|
|
|
|
|
United States of
America |
|
|
|
|
NUMBER OF SHARES
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
|
|
|
5. |
SOLE VOTING POWER |
|
|
|
|
|
0 |
|
|
|
|
6. |
SHARED VOTING POWER |
|
|
|
|
|
254,597 |
|
|
|
|
7. |
SOLE DISPOSITIVE
POWER |
|
|
|
|
|
0 |
|
|
|
|
8. |
SHARED DISPOSITIVE
POWER |
|
|
|
|
|
254,597 |
|
|
|
|
9. |
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
|
254,597 |
|
|
|
|
10. |
CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |
|
|
|
[_] |
|
|
|
11. |
PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW (9) |
|
|
|
|
|
4.99% |
|
|
|
|
12. |
TYPE OF REPORTING PERSON (SEE
INSTRUCTIONS) |
|
|
|
|
|
IN,
HC |
|
Item
1. |
(a). |
Name of
Issuer: |
|
|
|
|
|
|
|
InVivo Therapeutics Holdings Corp. |
|
|
|
|
|
|
(b). |
Address of Issuer's Principal
Executive Offices: |
|
|
|
One
Kendall Square, Suite B14402
Cambridge, Massachusetts 02139
United States of America
|
|
|
|
|
|
|
|
|
|
Item 2. |
(a). |
Name of Person
Filing: |
|
|
|
|
|
|
|
Armistice Capital, LLC
Armistice Capital Master Fund Ltd.
Steven Boyd
|
|
|
|
|
|
|
(b). |
Address of Principal Business
Office, or if None, Residence: |
|
|
|
|
|
|
|
Armistice Capital, LLC
510
Madison Avenue, 7th Floor
New
York, New York 10022
United States of America
Armistice Capital Master Fund Ltd.
c/o
dms Corporate Services Ltd.
20
Genesis Close
P.O.
Box 314
Grand Cayman KY1-1104
Cayman Islands
Steven Boyd
c/o
Armistice Capital, LLC
510
Madison Avenue, 7th Floor
New
York, New York 10022
United States of America
|
|
|
|
|
|
|
(c) |
Citizenship: |
|
|
|
|
|
|
|
Armistice Capital, LLC – Delaware
Armistice Capital Master Fund Ltd. – Cayman Islands
Steven Boyd – United States of America
|
|
|
|
|
|
|
(d). |
Title of Class of
Securities: |
|
|
|
|
|
|
|
Common Stock, $0.00001 par value |
|
|
(e).
|
CUSIP Number:
|
|
|
|
|
|
|
|
46186M506 |
|
Item 3. |
|
If This Statement is filed pursuant to
ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person
filing is a |
|
|
|
|
|
(a) |
[_] |
Broker or dealer registered under Section 15 of
the Exchange Act (15 U.S.C. 78c). |
|
|
|
|
|
(b) |
[_] |
Bank
as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C.
78c). |
|
|
|
|
|
(c) |
[_] |
Insurance company as defined in Section 3(a)(19)
of the Exchange Act (15 U.S.C. 78c). |
|
|
|
|
|
(d) |
[_] |
Investment company registered under Section 8 of
the Investment Company Act of 1940 (15 U.S.C. 80a-8). |
|
|
|
|
|
(e) |
[_] |
An
investment adviser in accordance with §
240.13d-1(b)(1)(ii)(E); |
|
|
|
|
|
(f) |
[_] |
An
employee benefit plan or endowment fund in accordance with
§
240.13d-1(b)(1)(ii)(F); |
|
|
|
|
|
(g) |
[_] |
A
parent holding company or control person in accordance with Rule
13d-1(b)(1)(ii)(G); |
|
|
|
|
|
(h) |
[_] |
A
savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C.1813); |
|
|
|
|
|
(i) |
[_] |
A
church plan that is excluded from the definition of an investment
company under Section 3(c)(14) of the Investment Company Act of
1940 (15 U.S.C. 80a-3); |
|
|
|
|
|
(j) |
[_] |
Group, in accordance with
s.240.13d-1(b)(1)(ii)(J). |
|
Item 4. |
Ownership. |
|
|
Provide the following information
regarding the aggregate number and percentage of the class of
securities of the issuer identified in Item 1. |
|
|
|
(a) |
Amount
beneficially owned: |
|
|
|
|
|
Armistice Capital, LLC – 254,597
Armistice Capital Master Fund Ltd. – 254,597
Steven Boyd – 254,597
|
|
|
|
|
(b) |
Percent of class: |
|
|
|
|
|
Armistice Capital, LLC – 4.99%
Armistice Capital Master Fund Ltd. – 4.99%
Steven Boyd – 4.99%
|
|
|
|
|
(c) |
Number of shares as
to which the person has: |
|
|
|
|
|
(i) |
Sole power to vote or to direct
the vote |
|
|
|
|
|
Armistice Capital, LLC – 0
Armistice Capital Master Fund Ltd. – 0
Steven Boyd – 0
|
|
|
|
(ii) |
Shared power to vote or to direct
the vote |
|
|
|
|
|
Armistice Capital, LLC – 254,597
Armistice Capital Master Fund Ltd. – 254,597
Steven Boyd – 254,597
|
|
|
|
(iii) |
Sole power to dispose or to
direct the disposition of |
|
|
|
|
|
Armistice Capital, LLC – 0
Armistice Capital Master Fund Ltd. – 0
Steven Boyd – 0
|
|
|
|
(iv) |
Shared power to dispose or to
direct the disposition of |
|
|
|
|
|
Armistice Capital, LLC – 254,597
Armistice Capital Master Fund Ltd. – 254,597
Steven Boyd – 254,597
|
|
|
|
|
|
|
|
|
|
Item
5. |
Ownership of
Five Percent or Less of a Class. |
|
|
|
If
this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check
the following [X]. |
|
|
|
|
|
Item
6. |
Ownership of
More Than Five Percent on Behalf of Another Person. |
|
|
|
If
any other person is known to have the right to receive or the power
to direct the receipt of dividends from, or the proceeds from the
sale of, such securities, a statement to that effect should be
included in response to this item and, if such interest relates to
more than five percent of the class, such person should be
identified. A listing of the shareholders of an
investment company registered under the Investment Company Act of
1940 or the beneficiaries of employee benefit plan, pension fund or
endowment fund is not required. |
|
|
N/A |
|
|
Item 7. |
Identification
and Classification of the Subsidiary Which Acquired the Security
Being Reported on by the Parent Holding Company. |
|
|
|
If a
parent holding company has filed this schedule, pursuant to Rule
13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an
exhibit stating the identity and the Item 3 classification of the
relevant subsidiary. If a parent holding company has
filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d),
attach an exhibit stating the identification of the relevant
subsidiary. |
|
|
N/A |
|
|
Item 8. |
Identification and Classification
of Members of the Group. |
|
|
|
If a
group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J),
so indicate under Item 3(j) and attach an exhibit stating the
identity and Item 3 classification of each member of the
group. If a group has filed this schedule pursuant to
§240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the
identity of each member of the group. |
|
|
N/A |
|
|
Item 9. |
Notice of Dissolution of
Group. |
|
|
|
Notice of dissolution of a group may be furnished
as an exhibit stating the date of the dissolution and that all
further filings with respect to transactions in the security
reported on will be filed, if required, by members of the group, in
their individual capacity. See Item 5. |
|
|
N/A |
|
|
Item 10. |
Certification. |
|
|
|
By signing below I certify that, to the best of
my knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities
and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect, other
than activities solely in connection with a nomination under §
240.14a-11. |
|
|
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.
|
Armistice
Capital, LLC* |
|
|
|
By: /s/ Steven
Boyd |
|
Steven Boyd |
|
Managing Member |
|
|
|
Armistice Capital Master Fund
Ltd. |
|
|
|
By: /s/ Steven
Boyd |
|
Steven Boyd |
|
Director |
|
|
|
|
|
/s/ Steven
Boyd* |
|
Steven Boyd |
* This Reporting Person disclaims beneficial ownership in the
Common Stock, except to the extent of his or its pecuniary interest
therein.
The original statement shall be signed by each person on whose
behalf the statement is filed or his authorized representative. If
the statement is signed on behalf of a person by his authorized
representative other than an executive officer or general partner
of the filing person, evidence of the representative's authority to
sign on behalf of such person shall be filed with the statement,
provided, however, that a power of attorney for this purpose which
is already on file with the Commission may be incorporated by
reference. The name and any title of each person who signs the
statement shall be typed or printed beneath his signature.
Note. Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits.
See s.240.13d-7 for other parties for whom copies are to be
sent.
Attention. Intentional misstatements or omissions of fact
constitute Federal criminal violations (see 18 U.S.C. 1001).
Exhibit A
AGREEMENT
The undersigned agree that this Schedule 13G dated April 24, 2020
relating to the Common Stock, $0.00001 par value, of InVivo
Therapeutics Holdings Corp. shall be filed on behalf of the
undersigned.
|
Armistice
Capital, LLC |
|
|
|
By: /s/ Steven
Boyd |
|
Steven Boyd |
|
Managing Member |
|
|
|
Armistice Capital Master Fund
Ltd. |
|
|
|
By: /s/ Steven
Boyd |
|
Steven Boyd |
|
Director |
|
|
|
|
|
/s/ Steven
Boyd |
|
Steven Boyd |
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Dec 2020 to Jan 2021
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Jan 2020 to Jan 2021